Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Socioeconomic predictors of human papillomavirus vaccination in Danish men - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Coitus is not recommended - a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: The novel BD Onclarity(TM) HPV assay (Onclarity) on the BD Viper™ LT system (BD Diagnostics, Sparks, MD), detects E6/E7 DNA from 13 high-risk HPV genotypes and HPV66. We compared the analytical and clinical performance of the Onclarity Assay to that of Hybrid Capture 2 and LINEAR ARRAY using adjudicated histological outcomes from Danish women referred for colposcopy.

METHODS: 276 women from Copenhagen, Denmark were referred for colposcopy with abnormal cytology and/or a positive HPV test. Two samples for HPV analysis were taken in BD SurePath™ and in the BD cervical brush diluent (CBD) media. ClinicalTrial gov. identifier: NCT01671462, Ethical Approval: H-4-2012-070.

RESULTS: Histology was normal in 84 (31%) women, 70 (26%) had CIN1, 47 (17%) CIN2, and 68 (25%) had CIN3. The Onclarity assay detected 67 out of 68 (99%) ≥CIN3 and 113/115 (98%) ≥CIN2. The specificities for <CIN2 were 21%, 17%, and 22%, for HC2, Onclarity and LA, respectively.

CONCLUSION: Overall, the Onclarity HPV assay performed well on SurePath LBC and CBD media, with clinical sensitivity and specificity matching those of HC2 and LA.

OriginalsprogEngelsk
TidsskriftPapillomavirus research (Amsterdam, Netherlands)
Vol/bind2
Sider (fra-til)31-37
Antal sider7
ISSN2405-8521
DOI
StatusUdgivet - dec. 2016

ID: 51951534